Qube Research & Technologies Ltd
Position in NAMS — NewAmsterdam Pharma Co N.V.
CIK 1729829
LONDON, X0
Position in NAMS
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$1,595,880
New position
Shares Held
47,090
first reported quarter
Ownership
0.039%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#98
of 198 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Jun 30, 2026Qube Research & Technologies Ltd holds $2,443,042,063 across 169 Biotechnology names. NAMS ranks #107 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
798,715 | $240,437,176 | |
| 2 | INSM |
INSMED Inc
|
1,682,334 | $179,370,451 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
221,607 | $138,180,828 | |
| 4 | ROIV |
Roivant Sciences Ltd.
|
3,454,496 | $122,254,613 | |
| 5 | AXSM |
Axsome Therapeutics, Inc.
|
426,336 | $104,354,262 | |
| 6 | APGE |
Apogee Therapeutics, Inc.
|
659,678 | $87,559,060 | |
| 7 | TVTX |
Travere Therapeutics, Inc.
|
1,443,230 | $81,989,896 | |
| 8 | RPRX |
Royalty Pharma plc
|
1,412,112 | $79,177,119 |
All Filings in NAMS
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,595,880 | 47,090 | Shares | Sole | 2026-08-14 | |
| No filing history on record for this holder in this stock. | ||||||